Solventum Co. (NYSE:SOLV) Shares Sold by FNY Investment Advisers LLC

FNY Investment Advisers LLC reduced its stake in Solventum Co. (NYSE:SOLV) by 43.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,250 shares of the company’s stock after selling 1,700 shares during the period. FNY Investment Advisers LLC’s holdings in Solventum were worth $148,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SOLV. MML Investors Services LLC raised its stake in shares of Solventum by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after acquiring an additional 168 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in Solventum by 4.2% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after purchasing an additional 200 shares during the period. IVC Wealth Advisors LLC raised its position in Solventum by 5.0% in the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock valued at $464,000 after purchasing an additional 318 shares during the period. KKM Financial LLC lifted its stake in Solventum by 7.9% during the third quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after purchasing an additional 319 shares in the last quarter. Finally, Copeland Capital Management LLC acquired a new stake in shares of Solventum in the third quarter valued at $26,000.

Solventum Stock Performance

NYSE SOLV opened at $70.25 on Wednesday. The firm has a 50 day moving average of $69.18 and a two-hundred day moving average of $65.24. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SOLV. Stifel Nicolaus began coverage on Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Mizuho initiated coverage on shares of Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target on the stock. Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Morgan Stanley increased their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Wolfe Research initiated coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Solventum has a consensus rating of “Hold” and an average price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.